|
Schirdewan博士的引述的參考文獻:
: z7 r, Y* M1 L5 Z
3 I& o* F# z8 h: ]' a, HCamm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. " K% `$ v9 S; a; i
1 y) v- W& \/ [Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 9 l0 {7 [& l4 ]/ s W
& s5 Q1 t3 s/ BRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
) P- |! i; p+ P3 P% H
3 c9 F4 l1 X0 @5 F關於BIOTRONIK SE & Co. KG
0 h7 {) F2 K9 M. I
7 i* G7 [1 K% [8 J) v( U4 l! S/ y. WBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|